BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vopimetostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vopimetostat\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06188702-2073@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Vopimetostat: Phase 1/2 readout est. (NCT06188702)
DESCRIPTION:Vopimetostat\, phase 1/2.\nStudy: S095035 as a Single Agent and
  in Combination in Adult Participants With Advanced or Metastatic Solid Tu
 mors With Deletion of MTAP\nEstimated primary completion: 1 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/vopimetostat#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06188702
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05732831-2073@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vopimetostat: Phase 1/2 readout est. (NCT05732831)
DESCRIPTION:Vopimetostat\, phase 1/2.\nStudy: Safety and Tolerability of TN
 G462 in Patients With MTAP-deleted Solid Tumors\nEstimated primary complet
 ion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vopim
 etostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05732831
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-2073@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vopimetostat: Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Vopimetostat\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study to Evaluate the Safety\, Tolerability & Efficacy of TNG462 in Combin
 ation in PDAC & NSCLC Patients\nEstimated primary completion: June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/vopimetostat#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06922591
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938463-2073@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Vopimetostat: Phase 1 readout est. (NCT07938463)
DESCRIPTION:Vopimetostat\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Lo
 rlatinib Plus TNG462 in ALK+ MTAP Del NSCLC\nEstimated primary completion:
  30 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vo
 pimetostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07938463
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897734-2073@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Vopimetostat: Phase 1/2 readout est. (NCT07897734)
DESCRIPTION:Vopimetostat\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 TNG462-C103: Study to Evaluate the Safety\, Tolerability\, and Antitumor A
 ctivity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Pa
 tients\nEstimated primary completion: November 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/vopimetostat#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07897734
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
